NCT03618537
Ixazomib Maintenance Study in Patients With AL Amyloidosis
At risk: Primary completion moved at least 11 months later.
See at-risk trials from Memorial Sloan Kettering Cancer Center
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 9 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Aug 2026 to Aug 2027
- Eligibility criteria expanded, about 42 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 47 to confirmed 17
- Site details revised at 8 of 8 sites
- Notable Primary and study completion dates: Aug 2023 to Aug 2026
- Study sites revised (8)
- Minor Site details revised at 1 of 8 sitesv9
- Minor Study sites revised (8)v6
Show 3 earlier versionsHide 3 earlier versions
- Notable Primary and study completion dates: Aug 2021 to Aug 2023v5
- Minor Study sites: 7 to 8v3
- Minor Study sites: 6 to 7v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Enrolled patients will receive ixazomib at a fixed dose of 4mg on days 1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle. Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue. Treatment cycles will be repeated until disease progression for up to 24 cycles or until development of significant treatment-related toxicities.
Drugs: Ixazomib, Dexamethasone
Sites
8 sites in 1 country